MARKET

QTTB

QTTB

Q32 BIO INC
NASDAQ
6.30
-0.52
-7.62%
Closed 19:20 03/16 EDT
OPEN
6.80
PREV CLOSE
6.82
HIGH
6.91
LOW
6.14
VOLUME
337.46K
TURNOVER
0
52 WEEK HIGH
7.80
52 WEEK LOW
1.345
MARKET CAP
92.17M
P/E (TTM)
2.602
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at QTTB last week (0309-0313)?
Weekly Report · 23h ago
Best Momentum Stocks to Buy for March 13th
NASDAQ · 3d ago
Small-Cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 3d ago
New Strong Buy Stocks for March 13th
NASDAQ · 3d ago
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Q32 Bio (QTTB)
TipRanks · 5d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI)
TipRanks · 5d ago
Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing
TipRanks · 6d ago
Positioning Bempikibart for Pivotal Development: De-Risked Economics, Strong Cash Runway, and a Catalyst-Rich 2026 Support Buy Rating
TipRanks · 6d ago
More
About QTTB
Q32 Bio Inc. is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb – CR1 fusion protein which demonstrated preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.

Webull offers Q32 Bio Inc stock information, including NASDAQ: QTTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QTTB stock methods without spending real money on the virtual paper trading platform.